Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial ResultsGlobeNewsWire • 02/25/21
Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/18/21
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company UpdatesGlobeNewsWire • 02/18/21
CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In MedicineForbes • 01/11/21
Genetics Stocks Pop After Intellia Offers Update For Gene-Editing DrugsInvestors Business Daily • 01/07/21
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021GlobeNewsWire • 01/07/21
Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking TodayThe Motley Fool • 12/29/20
Intellia Therapeutics: The Smallest Of The Big 3 CRISPR Companies Has Big PotentialSeeking Alpha • 12/23/20
Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure DivesInvestors Business Daily • 12/21/20
Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT DeficiencyGlobeNewsWire • 12/12/20